Yuling Luo, Ph.D.

Yuling is a technologist and serial entrepreneur and has spent his entire career in life sciences startup companies. He is currently the founder, chairman and CEO of Alamar Biosciences, a startup company developing game-changing technologies for early detection of cancer and other diseases. Yulong is the inventor of RNAscope, a breakthrough molecular detection technology that has become increasingly popular for life sciences research and diagnostics. As the founder, president and CEO of Advanced Cell Diagnostics (ACD), he led the company from concept to successful product launch and commercialization. Under his leadership, ACD has become one of the fastest growing life sciences company, which was acquired by Bio-Techne for $325M in 2016. Yuling and his team have created $300M value for ACD shareholders. Before ACD, Yuling was a co-founder of Panomics (previously named Genospectra before its acquisition of Panomics), a life sciences company that was acquired by Affymetrix in 2008. At Panomics, he served in various roles including vice president, Functional Genomics and chief scientific officer, and he led the development and launch of all its flagship products. Prior to Panomics, Yulong was one of the earliest senior scientists at Exelixis, now a NASDAQ company, where he led a team to identify and validate novel therapeutic targets. Yuling has published numerous research papers in top peer-reviewed journals and his inventions are the subject of more than 30 issued patents.

Yuling received a Bachelor of Science in Chemistry from the University of Science & Technology of China and earned a PhD in Biochemistry from Case Western Reserve University in Ohio.